Hepatocellular carcinomas expressing 'stemness'-related markers: Clinicopathological characteristics

Digestive Diseases

Volumn 32, Issue 6, 2014, Pages 778-785

  Kim, Haeryoung ^a   Park, Young Nyun ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; K19; Prognosis; Stemness

Indexed keywords

CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; ALPHA FETOPROTEIN; CELL ADHESION MOLECULE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR ANTIGEN; TUMOR MARKER; TUMOR-ASSOCIATED ANTIGEN GA733;

BILE DUCT CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LIVER BIOPSY; LIVER CELL CARCINOMA; METASTASIS; OVERALL SURVIVAL; PATHOGENESIS; PROTEIN EXPRESSION; TUMOR INVASION; CANCER STAGING; CANCER STEM CELL; CHEMISTRY; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; MALE; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; ANTIGENS, CD; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PEPTIDES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84910652799     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000368021     Document Type: Conference Paper

References (32)

1. Boyault S, Rickman DS, De Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52.
2. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-7392.
3. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-676.
4. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
5. Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J: A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 2013;145:176-187.
6. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW: EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-1461.
7. Govaere O, Komuta M, Berkers J, Spee B, Janssen C, De Luca F, Katoonizadeh A, Wouters J, Van Kempen LC, Durnez A, Verslype C, De Kock J, Rogiers V, Van Grunsven LA, Topal B, Pirenne J, Vankelecom H, Nevens F, Van Den Oord J, Pinzani M, Roskams T: Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut 2014;63:674-685.
8. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN: Human hepatocellular carcinomas with 'stemness'-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011;54:1707-1717.
9. Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T, Itakura J, Nakanishi H, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, Sakamoto M, Izumi N: Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 2011;80:278-288.
10. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K: Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851-857.
11. Lo RC, Ng IO: Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancers. Liver Cancer 2013;2:84-92.
12. Oishi N, Yamashita T, Kaneko S: Molecular biology of liver cancer stem cells. Liver Cancer 2014;3:71-84.
13. Theise ND, Curado MP, Franceschi S, Hytiroglou P, Kudo M, Park YN, Sakamoto M, Torbenson M, Wee A: Hepatocellular carcinoma; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System, ed 4. Lyon, IARC, 2010, pp 205-216.
14. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG: Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013;368:2266-2276.
15. Van Eyken P, Sciot R, Paterson A, Callea F, Kew MC, Desmet VJ: Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1988;19:562-568.
16. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY: Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996;149:1167-1175.
17. Wu PC, Lai VC, Fang JW, Gerber MA, Lai CL, Lau JY: Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 1999;31:965-966.
18. Yoon DS, Jeong J, Park YN, Kim KS, Kwon SW, Chi HS, Park C, Kim BR: Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. Yonsei Med J 1999;40:472-477.
19. Kim H, Yoo JE, Cho JY, Oh BK, Yoon YS, Han HS, Lee HS, Jang JJ, Jeong SH, Kim JW, Park YN: Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing 'stemness'-related markers. J Hepatol 2013;59:746-752.
20. Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, Yoo JE, Ahn EY, Kim GI, Choi JS, Kim YB, Park YN: A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology 2012;55:1776-1786.
21. Theise ND, Nakashima O, Park YN, Nakanuma Y: Combined hepatocellular-cholangiocarcinoma; in Bosman FT Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System, ed 4. Lyon, IARC, 2010, pp 225-227.
22. Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, Park YN: Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004;40:298-304.
23. Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, Tsui W, Ohta H, Nakanuma Y: Hepatic 'stem cell' malignancies in adults: four cases. Histopathology 2003;43:263-271.
24. Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, Kondo R, Nomura Y, Koura K, Ueda K, Sanada S, Naito Y, Yamaguchi R, Yano H: Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013;37:496-505.
25. Ikeda H, Harada K, Sato Y, Sasaki M, Yoneda N, Kitamura S, Sudo Y, Ooi A, Nakanuma Y: Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol 2013;140:329-340.
26. Jeong HT, Kim MJ, Kim YE, Park YN, Choi GH, Choi JS: MRI features of hepatocellular carcinoma expressing progenitor cell markers. Liver Int 2012;32:430-440.
27. Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Nakamoto Y, Yamamoto M, Takayama T, Arii S, Wang XW, Kaneko S: Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 2014, Epub ahead of print.
28. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49:138-151.
29. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC: From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004;3:73-81.
30. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, Yi NJ, Suh KS, Lee KU, Park ES, Thorgeirsson SS, Kim YJ: Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 2010;70:3034-3041.
31. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM: Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51.
32. Ji J, Wang XW: Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 2012;39:461-472.